In patients with wild-type transthyretin cardiac amyloidosis, there was a 14-month delay from initial clinical manifestations to suspected diagnosis, followed by 2.5 months to definite diagnosis.
Cross-Sectional (n=118)
Yes
There is a significant delay of 14 months from symptom onset to suspicion of wild-type transthyretin cardiac amyloidosis, but once suspected, definite diagnosis is achieved rapidly within 2.5 months.
Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) is an increasingly recognized disease in elderly individuals. We aimed to perform a cross-sectional survey investigating the current diagnostic journey of ATTRwt patients in the Czech Republic from initial symptoms to final diagnosis. Between November 2022 and May 2023, most data were prospectively obtained using a dedicated questionnaire from 118 ATTRwt-CA patients during the regular outpatient consultation. The rest of the data were taken by attending physicians from medical records. The mean age of the patients at the time of diagnosis was 77 ± 6 years, 85.6% were males. The time interval from the onset of clinical scenario leading to suspicion of CA to suspected diagnosis was 14±24 months, while the subsequent period to definite ATTRwt-CA diagnosis was 2.5±2.3 months. Heart failure primarily led to the suspicion of CA in 61.9%, followed by suspicious echocardiographic findings (12.7%) and atrial fibrillation or flutter (6.8%). The history of carpal tunnel syndrome was the most common extracardiac manifestation found in 53.9% subjects, with median duration of 99 months. The diagnosis of CA was most often first suspected by outpatient cardiologists (33.1%) and cardiologists working at a cardiocenter (25.4%). At the time of diagnosis, NYHA class I or II was present in 10% and 56% of patients, respectively. The definite ATTRwt-CA diagnosis was made noninvasively in 63% cases. A relatively long-time delay still exists between the onset of clinical manifestations and suspicion of CA. Nevertheless, once CA is suspected, the definite ATTRwt-CA diagnosis is made early. Although heart failure still represents the most common clinical scenario, several other clinical profiles lead quite frequently to suspicion of the disease. The non-invasive diagnostics of ATTRwt-CA is done in majority of our patients, who are diagnosed mostly in early stages of the disease. The awareness of ATTRwt manifestations must be increased in order to shorten the whole diagnostic process of the disease.
Chocholová et al. (Fri,) conducted a cross-sectional in Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) (n=118). Diagnostic journey assessment was evaluated on Time interval from onset of clinical scenario to suspected diagnosis (months). In patients with wild-type transthyretin cardiac amyloidosis, there was a 14-month delay from initial clinical manifestations to suspected diagnosis, followed by 2.5 months to definite diagnosis.